<DOC>
	<DOCNO>NCT01552603</DOCNO>
	<brief_summary>The purpose study verify automated system blood glucose control Type I Diabetics . The automated system consist investigational Artificial Pancreas Control software ( APC ) , two blood glucose sensor , two hormone pump , one delivering insulin lower blood sugar , second delivering glucagon raise blood sugar . The blood glucose sensor relay information Artificial Pancreas software , use Adaptive Proportional Device algorithm determine rate insulin glucagon infusion hormone pump . In prior study , Adaptive Proportional Device algorithm verify , require manual input computer hormone pump . This study differ use fully automated system control Artificial Pancreas Control software . The importance change next step enable outpatient use automate , close loop blood glucose control .</brief_summary>
	<brief_title>Artificial Pancreas Control System Inpatient Setting</brief_title>
	<detailed_description>The objective current human study verify component Artificial Pancreas Control system inpatient study . This master controller software design use conjunction two subcutaneous continuous glucose monitor system regulate blood glucose level well two Omnipod pump , one administer insulin one administering glucagon . The sensor communicate wirelessly two sensor receiver interfaced APC wireless USB connection . The insulin glucagon pump control APC wireless USB connection . The algorithm include APC automate version Adaptive Proportional Derivative ( APD ) insulin glucagon control algorithm , previously study investigational device . The APD study vivo ( 28 experiment , 33 hr length , manual adjustment pump ) serious adverse effect note . Manual input glucose sensor data insulin/glucagon infusion rate longer necessary . The APC test vivo 28 hour experiment inpatient set preparation outpatient testing .</detailed_description>
	<mesh_term>Diabetes Mellitus</mesh_term>
	<mesh_term>Diabetes Mellitus , Type 1</mesh_term>
	<mesh_term>Glucagon</mesh_term>
	<mesh_term>Pancrelipase</mesh_term>
	<mesh_term>Pancreatin</mesh_term>
	<criteria>Diagnosis type 1 diabetes mellitus least 1 year . Male female subject 21 65 year age . Current use insulin pump . Willingness follow study procedure , include attend clinic visit . Willingness sign inform consent HIPAA document . Pregnancy Lactation : For woman childbearing potential : requirement negative urine pregnancy test agreement use contraception study least 1 month participate study . Acceptable contraception include birth control pill / patch / vaginal ring , DepoProvera , Norplant , IUD , double barrier method ( woman use diaphragm spermicide man use condom ) , abstinence . Renal insufficiency ( serum creatinine 2.0 mg/dL great ) . Serum ALT AST equal great 3 time upper limit normal ; hepatic synthetic insufficiency define serum albumin le 3.3 g/dL ; serum bilirubin 2 . Adrenal insufficiency Hematocrit le equal 34 % . A history cerebrovascular disease coronary artery disease regardless time since occurrence . Congestive heart failure , NYHA class III IV . Diagnosis 2nd 3rd degree heart block arrhythmia judge investigator exclusionary . Any active infection . Visual impairment prevent read glucose meter value continuous glucose monitoring device . Physical impairment impede ability use glucose meter glucose monitoring device . Active foot ulceration . Severe peripheral arterial disease characterize ischemic rest pain severe claudication . Active alcohol abuse , substance abuse , severe mental illness ( judge principal investigator ) . Active malignancy , except basal cell squamous cell skin cancer . Major surgical operation within 30 day prior screen . Seizure disorder . Chronic usage immunosuppressive medication ( cyclosporine , azathioprine , sirolimus , tacrolimus ) . Current administration oral parenteral corticosteroid . Use investigational drug within 30 day prior screen . Bleeding disorder , treatment warfarin , platelet count 50,000 . Allergy aspart insulin . Allergy glucagon . Past history pheochromocytoma family history MEN 2 , neurofibromatosis , von HippelLindau disease . Insulin resistance require 200 unit per day . Need uninterrupted treatment acetaminophen . Intolerance mild hypoglycemia ( glucose 6070 mg/dl ) . History hypoglycemic unawareness . Insulin antibody level ≥ 100 µUnits/ml . C peptide level ≥0.5 ng/ml . Any concurrent illness , diabetes , control stable therapeutic regimen . Any reason principal investigator deem exclusionary</criteria>
	<gender>All</gender>
	<minimum_age>21 Years</minimum_age>
	<maximum_age>65 Years</maximum_age>
	<verification_date>April 2016</verification_date>
	<keyword>glucose sensor</keyword>
	<keyword>artificial pancreas</keyword>
	<keyword>Diabetes Mellitus</keyword>
</DOC>